Finkel, Richard S. http://orcid.org/0000-0002-9351-7054
Lorson, Christian L.
Article History
Received: 12 December 2021
Revised: 27 January 2022
Accepted: 18 February 2022
First Online: 8 March 2022
Competing interests
: RSF has served as an advisor to Biogen, AveXis/Novartis, Roche, ScholarRock, and Shift; has participated as an investigator in clinical trials of nusinersen, onasemnogene abeparvovec and risdiplam in patients with SMA. CLL is the co-founder and Chief Scientific Officer of Shift Pharmaceuticals.